Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12831345rdf:typepubmed:Citationlld:pubmed
pubmed-article:12831345lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:12831345lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:12831345lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:12831345lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:12831345lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:12831345pubmed:issue7lld:pubmed
pubmed-article:12831345pubmed:dateCreated2003-6-30lld:pubmed
pubmed-article:12831345pubmed:abstractTextRheumatoid arthritis is a chronic autoimmune disease characterised by inflammation of the synovial lining of joints and destruction of cartilage and bone. Many pro-inflammatory cytokines, chemokines and growth factors are expressed in diseased joints, and recognition of the key role of TNF-alpha led to the development of highly effective new therapies. TNF-alpha inhibitors, such as monoclonal anti-TNF-alpha antibody infliximab (Remicade), have demonstrated efficacy in clinical trials. It is now clear that TNF-alpha blockade, in addition to reducing joint inflammation and leukocyte infiltration, also results in decreased formation of new blood vessels in the synovium. Such mechanism of action studies are now paving the way for the development of the next generation of drugs for treatment of rheumatoid arthritis.lld:pubmed
pubmed-article:12831345pubmed:languageenglld:pubmed
pubmed-article:12831345pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12831345pubmed:citationSubsetIMlld:pubmed
pubmed-article:12831345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12831345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12831345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12831345pubmed:statusMEDLINElld:pubmed
pubmed-article:12831345pubmed:monthJullld:pubmed
pubmed-article:12831345pubmed:issn1354-3784lld:pubmed
pubmed-article:12831345pubmed:authorpubmed-author:PaleologEwaElld:pubmed
pubmed-article:12831345pubmed:issnTypePrintlld:pubmed
pubmed-article:12831345pubmed:volume12lld:pubmed
pubmed-article:12831345pubmed:ownerNLMlld:pubmed
pubmed-article:12831345pubmed:authorsCompleteYlld:pubmed
pubmed-article:12831345pubmed:pagination1087-95lld:pubmed
pubmed-article:12831345pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12831345pubmed:meshHeadingpubmed-meshheading:12831345...lld:pubmed
pubmed-article:12831345pubmed:meshHeadingpubmed-meshheading:12831345...lld:pubmed
pubmed-article:12831345pubmed:meshHeadingpubmed-meshheading:12831345...lld:pubmed
pubmed-article:12831345pubmed:meshHeadingpubmed-meshheading:12831345...lld:pubmed
pubmed-article:12831345pubmed:meshHeadingpubmed-meshheading:12831345...lld:pubmed
pubmed-article:12831345pubmed:meshHeadingpubmed-meshheading:12831345...lld:pubmed
pubmed-article:12831345pubmed:year2003lld:pubmed
pubmed-article:12831345pubmed:articleTitleThe therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.lld:pubmed
pubmed-article:12831345pubmed:affiliationKennedy Institute of Rheumatology, Faculty of Medicine, Imperial College, United Kingdom. e.paleolog@imperial.ac.uklld:pubmed
pubmed-article:12831345pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12831345pubmed:publicationTypeReviewlld:pubmed
pubmed-article:12831345pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed